Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Michael Greene who wrote (1807)	3/4/1999 9:46:00 PM
From: Anthony@Pacific	Read Replies (1) \| Respond to of 2135

ENMD<------DECEPTIVE PRESS RELEASE IS EXPOSED!! "EntreMed's agreement to work with Covance to produce the drug comes three weeks after Bristol-Myers Squibb Co. pulled out of an agreement to develop angiostatin for EntreMed.." THE FOLLOWING IS THE ENTIRE TEXT , A DECEPTIVE ATTEMPT BY ENMD TO decieve the public into think ing as is realted in the second paragraph, that Covance agreemnet replaces the Bristol Myers Agreement!!!! Page 1 of 3 BN EntreMed's Cancer Drug Angiostatin to Be Produced by Covance Mar 3 1999 5:37 EntreMed's Cancer Drug Angiostatin to Be Produced by Covance Rockville, Maryland, March 3 (Bloomberg) -- EntreMed Inc. said it's signed a letter of intent with Covance Inc. for production of EntreMed's experimental anti-cancer compound angiostatin. EntreMed's agreement to work with Covance to produce the drug comes three weeks after Bristol-Myers Squibb Co. pulled out of an agreement to develop angiostatin for EntreMed.. Covance, one of the world's largest drug development companies, already has a contract to produce endostatin, another experimental cancer-fighting drug, for EntreMed. The new partnership should allow EntreMed to produce the two compounds in sufficient quantities to finish laboratory tests and begin human trials by the end of the year, the Rockville, Maryland-based company said. ''We anticipate that our relationship with Covance will enable the production of sufficient clinical grade angiostatin to meet our aggressive development timetable,'' said Edward Gubish, EntreMed's senior vice president of research and development. Studies suggest angiostatin and endostatin can shrink tumors Page 2 of 3 in mice by halting the flow of blood into the growths. The safety and effectiveness of the drugs in humans has yet to be proven. EntreMed shares rose 1/2 to 19 5/8 yesterday. Shares of Princeton, New Jersey-based Covance rose 1/2 to 28 1/16. --Brian Reid in Washington (202) 624-1936 /mfr Story illustration: For a chart showing stock performance, type ENMD US <Equity> GP D <Go>. Company news: Industry news: ENMD US <Equity> CN EntreMed NI DRG Drugs BMY US <Equity> CN Bristol-Myers NI HEA Health care CVD US <Equity> CN Covance DES,FA,BQ,RV Regional news: News by category: NI US U.S NI COS Companies NI MD Maryland NI GEN General news NI NY New York NI MEDICAL Medical NI FDA FDA